ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

Home / NTIDC News / ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

NTIDC research is proud to be the only site in Dallas that has been dosing with long-acting, injectable HIV-treatment since 2014. It’s been quite a journey over the past 5 years working with ViiV healthcare and Janssen to help bring long acting injectable therapy to market.

When approved by the FDA some patients will be able to stop taking their pills for HIV and start receiving injectable therapy instead. This is ground breaking for HIV patients, and we are proud to be a part of it.

Click Here for More Information

North Texas Infectious Diseases